Chemopreventive Agents and P450 Inhibition
Chem. Res. Toxicol., Vol. 13, No. 4, 2000 251
(9) Langoue¨t, S., Coles, B., Morel, F., Becquemont, L., Beaune, P.,
Guengerich, F. P., Ketterer, B., and Guillouzo, A. (1995) Inhibition
of P4501A2 and P4503A4 by oltipraz results in reduction of
aflatoxin B1 metabolism in human hepatocytes in primary culture.
Cancer Res. 55, 5574-5579.
(10) Langoue¨t, S., Mahe´o, K., Berthou, F., Morel, F., Lagadic-Gossman,
D., Glaise, D., Coles, B., Ketterer, B., and Guillouzo, A. (1997)
Effect of administration of the chemoprotective agent oltipraz on
P4501A and P4502B in rat liver and rat hepatocytes in culture.
Carcinogenesis 18, 1343-1349.
(11) Mahe´o, K., Morel, F., Langoue¨t, S., Kramer, H., Le Ferrec, E.,
Ketterer, B., and Guillouzo, A. (1997) Inhibition of cytochromes
P-450 and induction of glutathione S-transferases by sulforaphane
in primary human and rat hepatocytes. Cancer Res. 57, 3649-
3652.
(12) Conaway, C. C., J iao, D., and Chung, F. L. (1996) Inhibition of
rat cytochrome P450 by isothiocyanates and their conjugates: a
structure-activity relationship study. Carcinogenesis 17, 2423-
2427.
(29) De Matteis, F., Gibbs, A. H., and Unseld, A. (1977) Loss of haem
from cytochrome P-450 caused by lipid peroxidation and 2-allyl-
2-isopropylacetamide. Biochem. J . 168, 417-422.
(30) Schaefer, W. H., Harris, T. M., and Guengerich, F. P. (1985)
Characterization of the enzymatic and nonenzymatic peroxidative
degradation of iron porphyrins and cytochrome P-450 heme.
Biochemistry 24, 3254-3263.
(31) Buege, J . A., and Aust, S. D. (1978) Microsomal lipid peroxidation.
Methods Enzymol. 52, 302-310.
(32) Moreau, N., Martens, T., Fleury, M. B., and Leroy, J . P. (1990)
Metabolism of oltipraz and glutathione reductase inhibition.
Biochem. Pharmacol. 40, 1299-1305.
(33) Shiraki, H., and Guengerich, F. P. (1984) Turnover of membrane
proteins: kinetics of induction and degradation of seven forms of
rat liver microsomal cytochrome P-450, NADPH-cytochrome
P-450 reductase, and epoxide hydrolase. Arch. Biochem. Biophys.
235, 86-96.
(34) Halpert, J . R., Guengerich, F. P., Bend, J . R., and Correia, M. A.
(1994) Selective inhibitors of cytochromes P450. Toxicol. Appl.
Pharmacol. 125, 163-175.
(13) Barcelo, S., Gardiner, J . M., Gescher, A., and Chipman, J . K.
(1996) P4502E1-mediated mechanism of anti-genotoxicity of the
broccoli constituent sulforaphane. Carcinogenesis 17, 277-282.
(35) Hammons, G. J ., Alworth, W. L., Hopkins, N. E., Guengerich, F.
P., and Kadlubar, F. F. (1989) 2-Ethynylnaphthalene as
a
mechanism-based inactivator of the cytochrome P-450 catalyzed
N-oxidation of 2-naphthylamine. Chem. Res. Toxicol. 2, 367-374.
(36) Yun, C.-H., Hammons, G. J ., J ones, G., Martin, M. V., Hopkins,
N. E., Alworth, W. L., and Guengerich, F. P. (1992) Modification
of cytochrome P450 1A2 enzymes by the mechanism-based
inactivator 2-ethynylnaphthalene and the photoaffinity label
4-azidobiphenyl. Biochemistry 31, 10556-10563.
(37) Guengerich, F. P. (1990) Mechanism-based inactivation of human
liver cytochrome P-450 IIIA4 by gestodene. Chem. Res. Toxicol.
3, 363-371.
(38) Bondon, A., Macdonald, T. L., Harris, T. M., and Guengerich, F.
P. (1989) Oxidation of cycloalkylamines by cytochrome P-450.
Mechanism-based inactivation, adduct formation, ring expansion,
and nitrone formation. J . Biol. Chem. 264, 1988-1997.
(39) Grimm, S. W., Dyroff, M. C., Philpot, R. M., and Halpert, J . R.
(1994) Catalytic selectivity and mechanism-based inactivation of
stably expressed and hepatic cytochromes P450 2B4 and 2B5:
implications of the cytochrome P450 2B5 polymorphism. Mol.
Pharmacol. 46, 1090-1099.
(40) Roberts, E. S., Hopkins, N. E., Zaluzec, E. J ., Gage, D. A., Alworth,
W. L., and Hollenberg, P. F. (1995) Mechanism-based inactivation
of cytochrome P450 2B1 by 9-ethynylphenanthrene. Arch. Bio-
chem. Biophys. 323, 295-302.
(14) Parikh, A., Gillam, E. M. J ., and Guengerich, F. P. (1997) Drug
metabolism by Escherichia coli expressing human cytochromes
P450. Nat. Biotechnol. 15, 784-788.
(15) Shimada, T., Yamazaki, H., Foroozesh, M., Hopkins, N. E.,
Alworth, W. L., and Guengerich, F. P. (1998) Selectivity of
polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and
1B1. Chem. Res. Toxicol. 11, 1048-1056.
(16) Gillam, E. M. J ., Baba, T., Kim, B. R., Ohmori, S., and Guengerich,
F. P. (1993) Expression of modified human cytochrome P450 3A4
in Escherichia coli and purification and reconstitution of the
enzyme. Arch. Biochem. Biophys. 305, 123-131.
(17) Sandhu, P., Guo, Z., Baba, T., Martin, M. V., Tukey, R. H., and
Guengerich, F. P. (1994) Expression of modified human cyto-
chrome P450 1A2 in Escherichia coli: stabilization, purification,
spectral characterization, and catalytic activities of the enzyme.
Arch. Biochem. Biophys. 309, 168-177.
(18) Prough, R. A., Burke, M. D., and Meyer, R. T. (1978) Direct
fluorimetric methods for measuring mixed-function oxidases.
Methods Enzymol. 52, 372-377.
(19) Yamazaki, H., Nakano, M., Gillam, E. M. J ., Bell, L. C., Guenger-
ich, F. P., and Shimada, T. (1996) Requirements for cytochrome
b5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline,
and N-nitrosodimethylamine by recombinant cytochrome P450
2E1 and by human liver microsomes. Biochem. Pharmacol. 52,
301-309.
(41) Raner, G. M., Chiang, E. W., Vaz, A. D. N., and Coon, M. J . (1997)
Mechanism-based inactivation of cytochrome P450 2B4 by alde-
hydes: relationship to aldehyde deformylation via a peroxyhemi-
acetal intermediate. Biochemistry 36, 4895-4902.
(42) Roberts, E. S., Hopkins, N. E., Foroozesch, M., Alworth, W. L.,
Halpert, J . R., and Hollenberg, P. F. (1997) Inactivation of
cytochrome P450s 2B1, 2B4, 2B6, and 2B11 by arylalkynes. Drug
Metab. Dispos. 25, 1242-1248.
(20) Halpert, J . R. (1995) Structural basis of selective cytochrome P450
inhibition. Annu. Rev. Pharmacol. Toxicol. 35, 29-53.
(21) Guengerich, F. P. (1999) Inhibition of drug metabolizing en-
zymes: Molecular and biochemical aspects. In Handbook of Drug
Metabolism (Wolf, T. F., Ed.) pp 203-227, Marcel Dekker, New
York.
(43) Roberts, E. S., Alworth, W. L., and Hollenberg, P. F. (1998)
Mechanism-based inactivation of cytochromes P450 2E1 and 2B1
by 5-phenyl-1-pentyne. Arch. Biochem. Biophys. 354, 295-302.
(44) Maxuitenko, Y. Y., Libby, A. H., J oyner, H. H., Curphey, T. J .,
MacMillan, D. L., Kensler, T. W., and Roebuck, B. D. (1998)
Identification of dithiolethiones with better chemopreventive
properties than oltipraz. Carcinogenesis 19, 1609-1615.
(45) Wang, J . S., Shen, X., He, X., Zhu, Y. R., Zhang, B. C., Wang, J .
B., Qian, G. S., Kuang, S. Y., Zarba, A., Egner, P. A., J acobson,
L. P., Munoz, A., Helzlsouer, K. J ., Groopman, J . D., and Kensler,
T. W. (1999) Protective alterations in phase 1 and 2 metabolism
of aflatoxin B1 by oltipraz in residents of Qidong, People’s Republic
of China. J . Natl. Cancer Inst. 91, 347-354.
(46) Wattenberg, L. W. (1987) Inhibitory effects of benzyl isothio-
cyanate administered shortly before diethylnitrosamines or benzo-
[a]pyrene on pulmonary and forestomach neoplasia in A/J mice.
Carcinogenesis 8, 1971-1973.
(47) Morse, M. A., Wang, C. G., Stoner, G. D., Mandal, S., Conrad, P.
B., Amin, S. G., Hetch, S. S., and Chung, F. L. (1989) Inhibition
of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced DNA
adduct formation and tumorigenicity in the lung of F344 rat by
dietary phenethyl isothiocyanate. Cancer Res. 49, 549-553.
(48) Stoner, G. D., Morrissey, D. T., Heur, Y. H., Daniel, E. M., Galati,
A. J ., and Wagner, S. A. (1991) Inhibitory effects of phenyl
isothiocyanate on N-nitrosobenzylmethylamine carcinogenesis in
the rat esophagus. Cancer Res. 51, 2063-2068.
(22) Omura, T., and Sato, R. (1964) The carbon monoxide-binding
pigment of liver microsomes. I. Evidence for its hemoprotein
nature. J . Biol. Chem. 239, 2370-2378.
(23) Guengerich, F. P. (1978) Destruction of heme and hemoproteins
by liver microsomal reduced nicotinamide adenine dinucleotide
phosphate-cytochrome P-450 reductase. Biochemistry 17, 3633-
3639.
(24) J osephy, P. D., Evans, D. H., Parikh, A., and Guengerich, F. P.
(1998) Metabolic activation of aromatic amine mutagens by
simultaneous expression of human cytochrome P450 1A2, NADPH-
cytochrome P450 reductase, and N-acetyltransferase in Escheri-
chia coli. Chem. Res. Toxicol. 11, 70-74.
(25) Parikh, A., J osephy, P. D., and Guengerich, F. P. (1999) Selection
and characterization of human cytochrome P450 1A2 mutants
with altered catalytic properties. Biochemistry 38, 5283-5289.
(26) Foroozesh, M., Primrose, G., Guo, Z., Bell, L. C., Alworth, W. L.,
and Guengerich, F. P. (1997) Aryl acetylenes as mechanism-based
inhibitors of cytochrome P450-dependent monooxygenase en-
zymes. Chem. Res. Toxicol. 10, 91-102.
(27) Bieder, A., Decouvelaere, B., Gaillard, C., Depaire, H., Heusse,
D., Ledoux, C., Lemar, M., Le Roy, J . P., Raynaud, L., Snozzi, C.,
and Gregoire, J . (1983) Comparison of the metabolism of oltipraz
in the mouse, rat and monkey and in man. Arzneim.-Forsch. 33,
1289-1297.
(28) Levin, W., Lu, A. Y. H., J acobson, M., Kuntzman, R., Poyer, J .
L., and McCay, P. B. (1973) Lipid peroxidation and the degrada-
tion of cytochrome P-450 heme. Arch. Biochem. Biophys. 158,
842-852.
(49) Prestera, T., Holtzclaw, W. D., Zhang, Y., and Talalay, P. (1993)
Chemical and molecular regulation of enzymes that detoxify
carcinogens. Proc. Natl. Acad. Sci. U.S.A. 90, 2965-2969.